Abcam, ab256841, Human ATF6 knockout HeLa cell lysate

Size: 1Kit
ATF6 KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 17 bp deletion in exon6 and 25 bp deletion in exon6 and 4 bp deletion in exon6.
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, 17 bp deletion in exon6 and 25 bp deletion in exon6 and 4 bp deletion in exon6.,
Disease:Adenocarcinoma

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-ATF6, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Activating Transcription Factor 6 (ATF6) also known as ATF 6 is a significant protein in the endoplasmic reticulum (ER) stress response. The ATF6 protein has a molecular weight of approximately 84 kDa. It expresses predominantly in the endoplasmic reticulum membrane and plays a critical role in the unfolded protein response (UPR). During ER stress ATF6 relocates to the Golgi apparatus where it undergoes cleavage to become an active transcription factor. This process helps the cell to manage the accumulation of unfolded proteins.
Biological function summary
ATF6 operates as part of the transcription regulation mechanisms responding to ER stress. The ATF6 protein is essential in managing the expression of chaperone genes and ER-associated degradation (ERAD) components thereby maintaining protein homeostasis. ATF6 itself does not operate within a traditional complex but its activation involves proteolytic cleavage which subsequently releases the active form to the nucleus where it influences gene expression to alleviate stress conditions.
Pathways
ATF6 is prominently involved in the unfolded protein response pathway which manages cell survival and stress adaptation. This pathway closely interacts with other proteins like IRE1 and PERK forming a network that modulates the transcription of UPR target genes. Additionally ATF6 contributes to checkpoint control pathways that stabilize cellular environment by regulating genes related to chaperone and protein folding.
Malfunction or dysregulation of ATF6 links to conditions like diabetes and neurodegenerative diseases. In diabetes improper ATF6 function affects insulin signaling and glucose homeostasis often alongside proteins such as XBP1. In neurodegenerative diseases an inappropriate response to ER stress influences the progression of disorders like Alzheimer's disease where protein misfolding and aggregation play pivotal roles. Understanding how ATF6 interplays with these diseases could lead to new therapeutic avenues.